A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis (NCT06975722)
A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.
Who can join: Review the eligibility criteria below.
Location: Investigational Site Number: 8400009 — Escondido, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (67 Sites)
Showing the first 25 of 67 sites.
- Investigational Site Number: 8400009 — Escondido, California
- Investigational Site Number: 8400006 — Lancaster, California
- Investigational Site Number: 8400025 — Thousand Oaks, California
- Investigational Site Number: 8400024 — Jacksonville, Florida
- Investigational Site Number: 8400030 — Kissimmee, Florida
- Investigational Site Number: 8400003 — Lighthouse PT, Florida
- Investigational Site Number: 8400001 — Miami, Florida
- Investigational Site Number: 8400011 — Miami, Florida
- Investigational Site Number: 8400010 — Palmetto Bay, Florida
- Investigational Site Number: 8400019 — Tampa, Florida
- Investigational Site Number: 8400018 — Marietta, Georgia
- Investigational Site Number: 8400005 — Iowa City, Iowa
- Investigational Site Number: 8400017 — Boston, Massachusetts
- Investigational Site Number: 8400012 — Wyoming, Michigan
- Investigational Site Number: 8400014 — St Louis, Missouri
- Investigational Site Number: 8400021 — New York, New York
- Investigational Site Number: 8400029 — Queens Village, New York
- Investigational Site Number: 8400002 — Chapel Hill, North Carolina
- Investigational Site Number: 8400013 — Harrisburg, Pennsylvania
- Investigational Site Number: 8400023 — Houston, Texas
- Investigational Site Number: 8400007 — Ogden, Utah
- Investigational Site Number: 0360003 — Brisbane, Queensland
- Investigational Site Number: 0360001 — Clayton, Victoria
- Investigational Site Number: 1560004 — Huizhou, Ghangdong
- Investigational Site Number: 1560005 — Guangzhou, Guangdong
📞 Contact the Study Coordinator
Phone: (800) 633-1610
Email: contact-us@sanofi.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ulcerative Colitis
- A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) — Dothan, Alabama
- Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis — San Diego, California
- A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants — Eden Prairie, Minnesota
- CP101 for the Treatment of Ulcerative Colitis — Boston, Massachusetts
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis — Los Angeles, California
- Angiographic Delivery of AD-MSC for Ulcerative Colitis — Rochester, Minnesota
Explore by condition: All Ulcerative Colitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.